HC Wainwright Cuts Soleno Therapeutics (NASDAQ:SLNO) Price Target to $100.00

Soleno Therapeutics (NASDAQ:SLNO) had its target price trimmed by HC Wainwright from $120.00 to $100.00 in a research report released on Wednesday morning, MarketBeat.com reports. The firm currently has a buy rating on the stock. HC Wainwright also issued estimates for Soleno Therapeutics’ Q1 2026 earnings at $0.93 EPS, Q2 2026 earnings at $1.02 EPS, Q3 2026 earnings at $1.15 EPS, Q4 2026 earnings at $1.56 EPS, FY2026 earnings at $4.65 EPS, Q1 2027 earnings at $1.58 EPS, Q2 2027 earnings at $1.78 EPS, Q3 2027 earnings at $1.96 EPS, Q4 2027 earnings at $2.18 EPS and FY2027 earnings at $7.50 EPS.

SLNO has been the subject of a number of other reports. Robert W. Baird set a $107.00 target price on Soleno Therapeutics in a report on Tuesday, January 13th. TD Cowen lowered their price objective on shares of Soleno Therapeutics from $120.00 to $85.00 and set a “buy” rating for the company in a research note on Thursday, February 26th. Wall Street Zen cut shares of Soleno Therapeutics from a “buy” rating to a “hold” rating in a report on Saturday, February 28th. Wells Fargo & Company cut their target price on shares of Soleno Therapeutics from $114.00 to $110.00 and set an “overweight” rating on the stock in a research note on Friday, February 27th. Finally, Weiss Ratings reissued a “sell (d-)” rating on shares of Soleno Therapeutics in a research report on Thursday, January 22nd. One equities research analyst has rated the stock with a Strong Buy rating, twelve have issued a Buy rating, one has issued a Hold rating and one has assigned a Sell rating to the company. According to MarketBeat, Soleno Therapeutics currently has an average rating of “Moderate Buy” and an average target price of $106.85.

Soleno Therapeutics Stock Up 2.9%

Soleno Therapeutics stock opened at $39.68 on Wednesday. The company has a market capitalization of $2.05 billion, a PE ratio of 172.53 and a beta of -3.16. The company has a debt-to-equity ratio of 0.11, a quick ratio of 5.55 and a current ratio of 5.80. Soleno Therapeutics has a fifty-two week low of $32.63 and a fifty-two week high of $90.32. The firm has a 50 day moving average price of $41.61 and a 200 day moving average price of $52.23.

Soleno Therapeutics (NASDAQ:SLNO) last released its quarterly earnings results on Wednesday, February 25th. The company reported $0.80 EPS for the quarter, topping the consensus estimate of $0.64 by $0.16. The firm had revenue of $91.73 million for the quarter, compared to analysts’ expectations of $88.55 million. Research analysts expect that Soleno Therapeutics will post -3.72 earnings per share for the current year.

Institutional Trading of Soleno Therapeutics

A number of large investors have recently made changes to their positions in the company. Wellington Management Group LLP raised its holdings in Soleno Therapeutics by 272.3% in the third quarter. Wellington Management Group LLP now owns 2,312,095 shares of the company’s stock valued at $156,298,000 after acquiring an additional 1,691,057 shares in the last quarter. Braidwell LP purchased a new stake in shares of Soleno Therapeutics in the 3rd quarter valued at approximately $86,662,000. Janus Henderson Group PLC raised its holdings in shares of Soleno Therapeutics by 18.5% in the 4th quarter. Janus Henderson Group PLC now owns 7,178,354 shares of the company’s stock valued at $332,302,000 after purchasing an additional 1,122,015 shares in the last quarter. Invesco Ltd. lifted its position in shares of Soleno Therapeutics by 132.3% during the 3rd quarter. Invesco Ltd. now owns 1,500,525 shares of the company’s stock worth $101,435,000 after purchasing an additional 854,551 shares during the last quarter. Finally, Commodore Capital LP lifted its position in shares of Soleno Therapeutics by 121.3% during the 3rd quarter. Commodore Capital LP now owns 1,350,000 shares of the company’s stock worth $91,260,000 after purchasing an additional 740,000 shares during the last quarter. 97.42% of the stock is currently owned by hedge funds and other institutional investors.

Soleno Therapeutics News Summary

Here are the key news stories impacting Soleno Therapeutics this week:

• Positive Sentiment: Q4 results topped expectations — Soleno reported Q4 revenue of $91.7M (above Street estimates) and beat on EPS, a near-term catalyst supporting the stock’s rise. TD Cowen maintained a Buy on the name after the print. Article Title
• Positive Sentiment: HC Wainwright kept a Buy rating and $100 target — The firm also raised several near-term EPS forecasts (Q1 2026 to $0.93 from $0.88; Q2 2026 to $1.02 from $1.00) and set an aggressive FY2027 view ($7.50), signaling confidence in longer-term revenue/earnings growth drivers.
• Neutral Sentiment: Analyst detail shows a mixed revision pattern — while Wainwright raised some short-term estimates and projected strong 2027 results, the firm simultaneously adjusted other quarterly numbers; the net effect is a bullish price target but with recalibrated 2026 timing.
• Negative Sentiment: Wainwright trimmed several 2026 quarter estimates and lowered FY2026 slightly — Q3 2026 was cut to $1.15 (from $1.24), Q4 2026 to $1.56 (from $1.70), and FY2026 to $4.65 (from $4.82). These downgrades suggest potential near-term execution or timing risks that could cap upside until 2026 cadence is clearer.

Soleno Therapeutics Company Profile

Soleno Therapeutics, Inc is a clinical‐stage biopharmaceutical company focused on the development and commercialization of therapies for rare and orphan diseases. Headquartered in Redwood City, California, Soleno leverages a precision medicine approach to identify and advance small‐molecule treatments that address underlying genetic and metabolic dysfunctions. The company’s scientific strategy centers on repurposing and reformulating existing compounds to maximize therapeutic benefit in underserved patient populations.

The company’s lead candidate, diazoxide choline controlled release (DCCR), is being investigated for the treatment of Prader-Willi syndrome (PWS), a complex neurodevelopmental disorder characterized by insatiable appetite, hormonal imbalances and behavioral challenges.